Pricing Cures For Sickle Cell Disease: Sen. Cassidy Weighs In

Price decisions based on straight calculation of medical costs avoided may overestimate value of a cure, Cassidy warns.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells

The considerations that manufacturers use in setting prices for curative treatments like gene therapy for sickle cell disease must go beyond a calculation of medical costs avoided and take into account factors such as existing co-morbidities, Sen. Bill Cassidy, R-La., advised at a policy conference in Washington DC Feb. 12.

Such an exercise would be crucial to establishing a “reasonable opening cost” for treatment, he told the conference, which was...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access